HER2-targeted therapies for HER2-positive early-stage breast cancer: present and future
Breast cancer (BC) has the second highest incidence among cancers and is the leading cause of death among women worldwide. The human epidermal growth factor receptor 2 (HER2) is overexpressed in approximately 20%-30% of BC patients. The development of HER2-targeted drugs, including monoclonal antibo...
Saved in:
Main Authors: | Luying Xu (Author), Yuxin Xie (Author), Qiheng Gou (Author), Rui Cai (Author), Rong Bao (Author), Yucheng Huang (Author), Ruisi Tang (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2024-09-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Neratinib for HER2-positive breast cancer with an overlooked option
by: Liting Guo, et al.
Published: (2023) -
Response to COVID-19 in the Central African Republic: Coping Strategies Combined With China's Experience
by: Qiheng Gou, et al.
Published: (2022) -
Present and future of breast cancer anti-Her-2-therapy
by: V. P. Letyagin
Published: (2014) -
Pim1 Kinase Inhibitors Exert Anti-Cancer Activity Against HER2-Positive Breast Cancer Cells Through Downregulation of HER2
by: Bo-Wei Wang, et al.
Published: (2021) -
Efficacy and safety of trastuzumab deruxtecan in the treatment of HER2-low/positive advanced breast cancer: a single-arm meta-analysis
by: Zongyu Li, et al.
Published: (2023)